Company: SION
Filing Date: 2025-01-17
Form Type: S-1
Source: 0001193125-25-008474
Chunk: 118

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-01-17
Form: S-1
Chunk 118
---
 from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements contained in this prospectus include, but are not limited to, statements about:

| • |     | the initiation, timing, progress and results of our research and development programs, preclinical studies and clinical 
 trials;                                                                                                                 |

| • |     | the ability of clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results, 
 and the ability of our preclinical studies to predict later clinical trial results;                                      |

| • |     | the timing, scope and likelihood of regulatory filings and approvals of our product candidates; |

| • |     | the implementation of our business model, and strategic plans for our business, programs, and current and future product 
 candidates;                                                                                                              |

| • |     | our ability to obtain additional cash and the sufficiency of our existing cash, cash equivalents and investments in 
 marketable securities to fund our future operating expenses and capital expenditure requirements;                   |

| • |     | the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; |

| • |     | the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our                                                                                                                                    
 potential and ability to successfully manufacture and supply our current and future product candidates for clinical trials and for commercial use, if approved; the scope of protection we are able to establish and maintain for intellectual property 
 rights covering our product candidates;                                                                                                                                                                                                                 |

| • |     | developments relating to our competitors and our industry, including competing product candidates and therapies; |

| • |     | existing regulations and regulatory developments in the U.S. and other jurisdictions; |

| • |     | expectations regarding future events under collaboration and licensing agreements, including potential future payments, as 
 well as our plans and strategies for entering into further collaboration and licensing agreements;                         |

| • |     | general economic, industry and market conditions, including rising interest rates and inflation; |

| • |     | our ability to attract and retain the continued service of our key personnel and to identify, hire